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Peripheral donor leukocytes prolong survival of rat renal allo- The ultimate goal in allotransplantation is modulation
grafts. of the immune response to produce tolerance to the graft
Background. The development of strategies to enhance the without the need of systemic immunosuppression [1]. Insurvival of transplanted organs and to potentially lower or even
recent clinical studies, concomitant donor bone marrowdiscontinue immunosuppressive therapy would represent a sig-
nificant advancement in post-transplant patient care. infusion at the time of cadaveric transplantation has been
Methods. We studied the effect of pretransplant infusion of attempted in humans as a means to improve the survival
donor leukocytes alone or in combination with a short course of vascularized organs [2–5] via enhancing microchimer-
of cyclosporine on the long-term outcome of a rat model of
ism, that is, the natural migration of bone marrow-kidney allograft.
derived donor leukocytes from the allograft to the recipi-Results. A single intravenous infusion of donor peripheral
blood leukocytes (100 3 106 cells) from Brown-Norway (BN) ent organs and tissues [6–8]. The strategy of infusing
rats into major histocompatibility complex (MHC) incompati- donor bone marrow at the same time or shortly after
ble Lewis recipients largely failed to prolong kidney allograft transplantation of whole organs is merely an augmen-viability from the same donor transplanted 60, 40, or 30 days
tation of the normal post-transplant cell migration [8, 9].after cell infusion. A short course of cyclosporine (per se, unable
to prolong graft survival) was started at the same day of donor Concomitant donor bone marrow and organ transplanta-
leukocyte infusion, but instead was able to prolong the survival tion enhances the amount of the so-called “passenger”
of the BN kidney transplant—performed 40 days later—but leukocytes, which are cells consisting mainly of bone
not of a Wistar Furth (WF) third party, with some animals
marrow-derived dendritic cell progenitors [6–8]. Theyeven developing tolerance. A mixed lymphocyte reaction of
are capable of homing to secondary lymphoid tissueshost cells from long-term surviving rats to BN stimulator cells
was significantly reduced as compared with controls. Donor and to present antigen to T cells therein [10–13]. There
BN DNA was detected in the peripheral blood of Lewis rats has been increased speculation that such immature den-
until day 40 after BN leukocyte infusion. Microchimerism per- dritic cells present in nonlymphoid organs may constitutesisted (60 to 70 days post-transplant) in most long-term graft
tolerogenic progenitors of chimeric cells in recipient ofrecipients. Reducing the time interval between donor leukocyte
organ allografts [7–9]. Enhancing microchimerism by us-infusion and subsequent kidney transplant to 10 days still pro-
longed graft survival. Donor peripheral blood mononuclear ing bone marrow, however, predisposes individuals to
cells, but not polymorphonuclear cells, in the leukocyte prepa- graft-vs.-host disease (GVHD), as has been documented
ration contributed to prolong kidney allograft survival.
in recent clinical trials [4, 5], given its multilineage cellConclusions. Pretransplant donor leukocyte infusion under
composition, including T cells that drive the adversethe appropriate conditions can tip the immune balance toward
improved graft acceptance. This result could be relevant to the reaction against the graft recipient. Moreover, with this
achievement of donor-specific tolerance of the graft with the strategy, tolerance has been achieved only in animal
maintenance of an intact response to third-party antigens. recipients conditioned with a myeloablative [14] or non-
myeloablative [15, 16] dose of whole body irradiation to
permit major histocompatibility complex (MHC)–mis-Key words: microchimerism, transplantation, cyclosporine, rat MHC
class II gene, mononuclear leukocyte. matched bone marrow engraftment, which, however,
precludes its use in clinical organ transplantation. On
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sion on the possibility of achieving a drug-free allograft- 106 per rat) as mentioned earlier in this article. Starting
on the day of cell infusion, Lewis rats also received atolerant state.
In rats, combining multiple organ grafts (two hearts daily intramuscular (i.m.) injection of 10 mg/kg/day CsA
(Novartis, Basel, Switzerland) for 14 days and were sup-and two kidneys, for instance) with peritransplant infu-
sion of donor spleen leukocytes prolonged incompatible plemented with single injections on days 21 and 28. Forty
days after leukocyte infusion, these animals underwentgraft survival for more than 200 days [17], but leaves
unanswered the question of whether the observed tolero- kidney transplant from the same BN donor strain. A
similar protocol was followed with native Lewis rats whogenic effect was actually caused by the large mass of
donor tissue or to the simultaneous load of leukocytes. were treated with CsA but did not receive BN leukocytes
(group 6, N 5 6). The time schedule of administrationWith this background, our study was designed to ex-
plore the property of pretransplant infusion of donor of CsA was chosen according to previous findings of
successful engraftment with this regimen but using ta-leukocytes alone or in combination with a short course
of cyclosporine (CsA), to possibly prolong graft survival crolimus instead of CsA [18]. Moreover, to assess
whether the potential tolerogenic effect of the peripheralin a rat model of single kidney allograft as an alternative
to bone marrow infusion. blood leukocytes is donor specific, two additional groups
of animals were considered. In group 7 (N 5 4), Lewis
rats underwent the same protocol as discussed earlier in
METHODS
this article, but received a third-party WF kidney allo-
Animals graft 40 days after BN peripheral blood leukocyte infu-
sion. In group 8 (N 5 4), Lewis rats received peripheralInbred male rats weighing 175 to 200 g were used in
all experiments (Charles River Italia S.p.a., Calco, Italy). blood leukocytes (100 3 106 per experiment) from third-
party WF rats and 40 days later received a BN kidneyLewis rats (LW, RT1l) acted as recipients, and Brown-
Norway rats (BN, RT1n) or Wistar Furth (WF, RT1u) allograft. An additional control group of Lewis rats
(group 9, N 5 3) did receive the BN kidney allograftacted as donors. Animal care and treatment were con-
ducted in conformity with institutional guidelines in com- alone.
In all of these studies, kidney graft function was moni-pliance with national and international laws and policies
(EEC Council Directive 86/609, OJL 358, December tored by determining the 24-hour urine output in individ-
ual metabolic cages every other day during the first week1987; “Guide for the Care and Use of Laboratory Ani-
mals,” U.S. National Research Council 1996). Animals of post-transplantation. Blood samples were also col-
lected for measurement of the serum creatinine levelwere maintained in conventional animal facilities and
had free access to standard rat chow and tap water. (Reflotont; Boehringer Mannheim, Milan, Italy) twice
a week or at sacrifice or every month post-transplant.
Experimental design Operational tolerance was determined by kidney graft
survival considered synonymous with recipient death, orWe first evaluated the potential role of donor periph-
eral blood leukocytes to prolong graft survival by infus- sacrifice before then because of its moribund state.
Peripheral blood mononuclear cells (PBMCs) froming the preparation at different time points before kidney
transplantation without any immunosuppressants. Thus, long-term surviving recipients who were previously given
BN peripheral blood leukocytes and kidney from thenaive Lewis rats were given an intravenous injection of
BN peripheral blood leukocytes (100 3 106 per rat) under same donor strain were tested for their ability to prolifer-
ate in vitro to BN spleen cells in a standard one-waylight anesthesia 60 days (group 1, N 5 4), 40 days (group
2, N 5 5), and 30 days (group 3, N 5 7) before kidney mixed lymphocyte reaction (MLR) assay. As a control,
the MLR response of PBMCs from Lewis rats that re-transplantation from the same BN donor strain. As a
control (group 4, N 5 3), Lewis rats received a BN ceived BN kidney allografts but were pretreated with
WF peripheral blood leukocytes (third party) to BNkidney allograft alone. Graft function was monitored
thereafter. spleen cells was performed.
To assess whether the short course of CsA may addWe then explored the possibility that concomitant
short-course immunosuppression at the time of donor benefit to the potential tolerogenic effect of donor leuko-
cyte infusion by enhancing cell engraftment in the recipi-leukocyte infusion may afford any additional benefit to
the potential tolerogenic effect of this strategy. To ad- ents, cellular microchimerism in the peripheral blood
was serially determined at given time points after donordress this issue, experiments were performed using an
approach similar to that recently reported by Murase et cell infusion. Lewis rats received 100 3 106 donor BN
peripheral blood leukocytes with (group 10, N 5 3) oral, with combined bone marrow infusion and liver or
heart transplantation in a Lewis to BN rat combination without (group 11, N 5 3) a concomitant short course
of CsA. Blood was collected from a peripheral vein at[18]. Lewis rats (group 5, N 5 16) were given an intrave-
nous injection of BN peripheral blood leukocytes (100 3 5 minutes, 1 hour, and 1, 2, 10, 20, and 40 days after
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donor BN leukocyte infusion, and chimerism evaluated placed in an iced saline solution until transplant. Lewis
recipients were prepared by removal of the left kidney.as described later in this article. Moreover, the presence
of microchimerism was also determined 60 to 70 days An anastomosis was created between the recipient and
the donor renal artery, as well as the renal vein withpost-transplant in the peripheral blood of six long-term
kidney graft recipients previously infused with BN donor end-to-end anastomosis. The vascular clamps were re-
leased as soon as the vascular anastomoses were com-leukocytes.
We also examined whether or not repeated adminis- pleted, with an ischemia time of 20 to 30 minutes. Donor
and recipient ureters were attached end to end. Thetration of donor leukocytes to the naive Lewis rats in
order to enhance the antigen loading further may sensi- native right kidney was then removed, and the rats were
allowed to recover in their cages.tize the recipients and differently affect kidney graft sur-
vival. To this purpose, Lewis rats received two intrave-
Isolation and preparation of donor leukocytesnous infusions of 100 3 106 peripheral blood leukocytes
from BN rats at day 0 and seven days later (day 7) Leukocytes were isolated from heparinized venous
blood collected by cardiac puncture of BN rats. Bloodin the study protocol (group 12, N 5 8). The time of
administration of CsA was the same as for the single was mixed with Emagelt (Hoechst Marion Roussel, Mi-
lan, Italy), and erythrocytes were allowed to sediment.infusion of donor cells. Forty days after the first cell
infusion, the animals underwent BN kidney transplant, The leukocyte-enriched supernatant obtained after 40
minutes of incubation at 48C was then removed andand graft survival was monitored thereafter, as discussed
earlier in this article. centrifuged for 8 minutes at 48C. The remaining erythro-
cytes in the cell pellet were removed by ammonium chlo-Next, we attempted to reduce the time interval be-
tween donor cell infusion and transplantation. Thus, ride lysis at 48C and subsequent centrifugation.
Peripheral blood mononuclear cells were isolatedLewis rats (group 13, N 5 5) were given 100 3 106 BN
peripheral blood leukocytes and a 10 day course of CsA from BN whole blood by density gradient centrifugation
using Lympholyte-Rat (density, 1.094 g/ml; Cedarlane,(10 mg/kg/day intramuscularly). Ten days after cell infu-
sion, the animals underwent kidney transplant from the Ontario, Canada). The PMN-enriched preparation was
obtained by centrifugation of whole blood on Lympho-same BN donor strain, and CsA was discontinued. Simi-
larly, an additional group of Lewis rats (group 14, N 5 4) lyte-Mammal (density, 1.086 g/ml; Cedarlane). The pellet
containing PMNs and red blood cells was treated astreated with the same short course of CsA but without
BN leukocytes received a BN kidney allograft 10 days described for total leukocyte preparation.
Trypan blue exclusion testing always showed a moreafter starting the immunosuppressants.
We then investigated whether a particular cell popula- than 90% cell viability before intravenous injection into
the penile vein of the Lewis recipient. The cell count oftion, among peripheral blood leukocytes, may be respon-
sible for the potential tolerogenic effect of this cell infu- leukocyte suspension was determined to allow a uniform
cell dose and therefore an adequate comparison of thesion. Lewis rats were intravenously given BN PBMCs
(70 3 106 per experiment, N 5 6, group 15) or an enriched results.
preparation of BN polymorphonuclear cells (PMNs;
Mixed lymphocyte reaction30 3 106 per experiment, N 5 3, group 16) under the
same immunosuppression regimen with CsA, as de- Peripheral blood mononuclear cells were isolated
from Lewis rats on density gradient using the Lympho-scribed earlier in this article. This number of cells reflects
the relative contribution of the two populations to the lyte Rat. The latter cells (6 3 105) were mixed with 6 3
105 allogeneic spleen cells from BN rats that had beentotal number of 100 3 106 peripheral blood leukocytes
(70% PBMCs and 30% PMNs) infused in the first set irradiated (4000 rad) in vitro and cultured in tissue cul-
ture tubes in 1.2 ml culture medium, RPMI-1640 supple-of experiments. Forty days after cell infusion, the animals
were transplanted with a BN kidney, and graft survival mented with 2 mm l-glutamine, 100 mg/ml streptomycin,
100 U/ml penicillin, 0.05 mm 2-mercaptoethanol, 1 mmwas monitored thereafter.
pyruvic acid, and 20% fetal bovine serum (FBS). After
Kidney transplantation three days of culture, 200 ml of each tube were trans-
ferred in triplicate in 96-well round-bottomed plates andOrthotopic kidney transplantation was performed as
previously described [19]. BN donor animals were anes- pulsed for 18 hours with 3H-thymidine (1 mCi/well;
Amersham International, Buckinghamshire, UK). Cellsthetized with leptofen (1 mg/kg i.m.). The left kidney
was prepared by freeing the ureter from the attachments. were then harvested, and their 3H-thymidine uptake was
measured with a b counter. In each experiment, controlThe renal artery was separated from the renal vein by
blunt dissection. The donor kidney and ureter were re- combinations of Lewis PBMCs and irradiated Lewis
spleen cells were performed. The stimulation index (SI)moved en bloc and flushed with normal saline solution
containing 1000 UI/ml heparin. Then the kidney was was calculated using the following formula:
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SI 5
CPM in allogeneic MLR
CPM in control combinations
where CPM is counts per minute.
Analysis of chimerism
The chimerism was first evaluated by flow cytometry
assay using a donor-specific MHC class I antibody. Pe-
ripheral blood was obtained from the tail vein of Lewis
rats into a heparinized syringe, and leukocytes in whole
blood labeled with the monoclonal antibody from OX27
clone (Serotec, Oxford, UK), which recognizes rat MHC
class I RT1n (BN) but not RT1l (Lewis). Washed cells
were then stained with FITC-conjugated secondary anti-
body to mouse IgG precleared for rat IgG (Serotec),
treated with ammonium chloride to lyze red blood cells,
and analyzed by flow cytometry using a FACSort appara-
tus (Becton Dickinson, San Jose`, CA, USA). Examining
peripheral leukocytes of Lewis rats given in addition to
BN leukocytes a short course of CsA, positive cells were
found up to 20 days after cell infusion. However, we
also observed that in Lewis rats given the same CsA
treatment but not BN donor cells, the peripheral leuko-
cytes were also stained for BN MHC class I antigen,
indicating an artifact induced by the drug that probably
enhances the unspecific binding of both primary and
secondary antibodies (Fig. 1). In contrast, peripheral leu-
kocytes from untreated Lewis rats were never stained
by OX27 antibody.
The peripheral blood chimerism was then assessed
with polymerase chain reaction (PCR) by using specific
primers for the donor BN MHC class II RT1.Bbn. Be-
cause only few short fragments of MHC class II of BN
rats were reported in gene banks, we began by cloning
the highly polymorphic RT1.Bbn exon 2. A 336 bp frag-
ment containing exon 2 was amplified from genomic BN
DNA by designing PCR primers homologous to evo-
lutionary-conserved mouse intron sequences flanking
the exon [20]. The amplified product was ligated into
pCR2.1 vector (TA cloning; Invitrogen, Leek, The Neth-
erlands) and sequenced by dideoxynucleotide sequenc-
ing (Sequenase Version 2.0; United States Biochemical,
Cleveland, Ohio, USA). To eliminate potential errors Fig. 1. FACS profile of Lewis peripheral blood lymphocytes stained
for major histocompatibility complex (MHC) class I as described in theintroduced by PCR, several independent clones were
Methods section. Lymphocyte population was recognized on the basis ofanalyzed. The obtained sequence overlapped with a pre-
its light scattering parameters. Symbols are: (open histogram) secondary
viously reported RT1.Bbn fragment (GenBank M76781; antibody alone; (gray histogram) MHC class I staining. (A) Control
Lewis rat. (B) Lewis rat 10 days after donor Brown-Norway (BN)Fig. 2) from base 98 to 226, with two nucleotide differ-
leukocyte infusion and CsA treatment. (C) Lewis rat after 10 days CsAences at bases 140 and 195. Alignment of BN sequences
treatment.
with the correspondent Lewis sequence RT1.Bbl is
shown in Figure 2.
For microchimerism analysis, blood was collected
from the rat tail vein on ethylenediaminetetraacetic acid trophotometer, aliquoted, and stored at 48C until an-
(EDTA)-containing tubes. Genomic DNA was isolated alysis. Specific primers (59-CGCAGGGGATTTCGT
from buffy coats with a DNA extraction kit (Nucleon ATT-39, p1; 59-GGTGGGGACCTCCGTCT-39, p2) were
designed on the basis of the BN RT1.Bbn sequence ob-BACC 2; Amersham), quantitated on an ultraviolet spec-
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Fig. 2. Nucleotide sequence of exon 2 (capi-
tal letters) and partial intron sequences (small
letters) of MHC class II RT1.Bbn obtained
by cloning. This sequence was aligned with
RT1.Bbl sequence (X56596) and with a pre-
viously described fragment of RT1.Bbn exon
2 (M76781). Underlined are the sequence of
primers 1, 2, and 3 (p1, p2, p3) used for mi-
crochimerism evaluation. Only different nu-
cleotides are shown in the figure, and identical
nucleotides are indicated by dashes. This se-
quence is available from GenBank under ac-
cession number AF 113922.
tained by cloning. The PCR reactions were done with identical except for the initial hot start (10 min) and for
the number of cycles that was reduced to 32. In these100 ng of the DNA template, 18 pmol of forward and
reverse primers, 200 mm dNTPs, 1.5 mm MgCl2, 1 3 experimental conditions, Lewis DNA did not amplify.
PCR products were analyzed by electrophoresis in 1%GeneAmp II PCR buffer (10 mm Tris HCl, pH 8.3, 50
mm KCl), and 1 U AmpliTaqGold (Perkin-Elmer, NJ, agarose gel with 1 mg/ml ethidium bromide added for
ultraviolet visualization.USA) in a final volume of 20 ml. The PCR reaction was
performed in a Perkin-Elmer 9700 thermal cycler by
Statistical analysis60 cycles of denaturation (948C, 45 seconds), annealing
(588C, 30 seconds), and extension (728C, 30 seconds) Statistical analysis of kidney graft survival was per-
with a pre-PCR heat step of five minutes. This method formed using PROC LIFETEST of SAS 6.12, and sig-
specifically detected BN DNA (PCR product 256 bp) at nificance of difference between groups was determined
a 1:1000 dilution in Lewis DNA. No signal was found by log-rank test. Analysis of MLR results was performed
by one-way analysis of variance (ANOVA). Statisticalwith DNA from naive Lewis rats.
significance was defined as P , 0.05.By a second PCR round, BN DNA could be specifi-
cally detected until the dilution was larger than 1:2500
in the presence of Lewis DNA. One microliter of the
RESULTSfirst PCR product, previously diluted 1:200 in water, was
Donor peripheral blood leukocyte infusion and kidneyused as a template, and a more internal forward primer
graft survivalwas used in combination with the same reverse primer
of the first amplification (59-ACGCAGCGCATACG Table 1 shows kidney allograft survival in Lewis rats
receiving BN donor peripheral blood leukocyte infusionGCTC-39, p3; 59-GGTGGGGACCTCCGTCT-39, p2;
PCR product 204 bp). The PCR reaction conditions were at different time points before transplantation. One out
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Table 1. Effect of pretransplant donor peripheral blood leukocyte (group 7) rejected their graft within nine days after trans-
infusion at different times before transplantation on Brown-
plantation. Seventy-five percent of animals pretreatedNorway (BN) kidney allograft survival in Lewis rats
with the third-party WF peripheral blood leukocyte infu-
Time of BN leukocyte infusion Kidney graft survival sion (group 8) had only a minor prolongation of BNGroups days pre-transplant days
kidney graft survival, up to 25 days postsurgery (P 5
Group 1 Day 60 7, 7, 8, 67
0.014 vs. group 9, P 5 0.0084 vs. group 7, P 5 0.0034Group 2 Day 40 7, 7, 7, 7, 24
Group 3 Day 30 6, 6, 6, 7, 12, 56, .70 vs. group 6). Untreated control animals rejected the
Group 4 Control (no cell infusion) 7, 8, 13 allograft within nine days of their kidney transplant
(group 9).
The long-term surviving animals pretreated with BN
donor leukocyte preparation (group 5) had a normal or
of four rats (25%) given the donor leukocyte preparation moderately impaired renal function 60 days after trans-
60 days before transplantation had a graft survival that plantation (serum creatinine, range 0.89 to 2.35 mg/dl).
was prolonged up to the 67th postoperative day. The In the same group, those rats that developed graft rejec-
remaining transplanted animals rejected their grafts tion had elevated serum creatinine values at the time
within eight days postsurgery. Similarly, infusion of do- of sacrifice (range 1.83 to 5.55 mg/dl). In all control
nor leukocytes 40 days before kidney transplant did not rats given CsA alone, graft failure was associated with
provide any substantial benefit, because the graft sur- elevated serum creatinine values (range 6.23 to 7.60
vived up to 24 days postsurgery in only one rat (20%). mg/dl). The same occurred in transplanted animals re-
Further reduction in the interval between leukocyte infu- ceiving the third-party WF kidney graft (group 7), and
sion and kidney transplant to 30 days prolonged graft their serum creatinine concentration at the time of graft
survival in one rat (day 56) and induced tolerance in failure ranged from 3.61 to 6.06 mg/dl. In group 8 trans-
another one (more than 70 days; 28.5%), but all of the planted animals given the third-party WF leukocyte
remaining animals rejected their graft within 12 days preparation, serum creatinine ranged from 1.97 to 2.50
postsurgery. In control rats given a kidney transplant mg/dl.
alone, the graft failed within the 13th postoperative day. In long-term surviving rats of group 5, systemic unre-
sponsiveness was established by evaluating the func-
Effect of combined immunosuppression and donor tional status of T cells on the MLR in vitro. Figure 4
peripheral blood leukocyte infusion on shows the stimulation index (SI) of untreated Lewis rats
allograft survival as compared with that of tolerant and third-party kidney
Lewis rats, which also received short-term CsA at the graft-rejecting hosts. The SI of the untreated control
time of donor cell infusion, were healthy during the 40 responder cells to BN stimulator cells was, on average,
days after cell infusion and before kidney transplant. In 16.7. By contrast, the MLR response of the tolerant host
the same period, body weight increased from baseline cells was markedly and significantly reduced with a mean
values of 175 to 322 g (group 5) and from 178 to 314 g SI of 2 (P , 0.05 vs. untreated controls). On the other
(group 7). Similar body weight gain was observed in hand, the proliferative response of cells from Lewis ani-
group 8 rats that received WF leukocytes 40 days before mals pretreated with WF leukocyte infusion and re-
BN kidney allograft (175 to 320 g). Rats given CsA alone jecting a BN kidney allograft was blunted, but still four
were similarly healthy, and their body weights (176 to times higher than that of cells from tolerant animals
328 g) increased to a comparable extent as those animals (P 5 NS vs. untreated controls).
given the leukocyte suspension.
Analysis of microchimerism in the peripheral blood ofFigure 3 shows kidney graft survival in these five
Lewis recipients of donor leukocytes with orgroups of animals. All rats given the infusion of periph-
without cyclosporineeral blood leukocytes under the short course of CsA
(group 5) had prolonged survival of their kidney allo- To detect donor microchimerism in Lewis peripheral
grafts (median survival, 53 days; P 5 0.0001 vs. group blood, we designed a set of primers capable of detecting
6, 7, 9 and P 5 0.0012 vs. group 8). Sixty-eight percent nucleotide differences for RT1.Bb genes of the donor
of these animals rejected their graft within 20 to 69 days and recipient. The specificity and sensitivity of these
post-transplant, whereas in the remaining rats a state of primers was first tested using genomic BN DNA serially
tolerance developed, as documented by a graft survival diluted with a constant amount of Lewis DNA. As shown
of more than 70 days. At variance, rats treated with CsA in Figure 5, this method specifically detected BN DNA
alone in the pretransplant period (group 6) invariably at more than a 1:2500 dilution in the presence of Lewis
rejected kidney graft within eight days of postsurgery. DNA.
Similarly, Lewis rats given BN peripheral blood leuko- Then, the blood samples from Lewis rats infused with
BN peripheral blood leukocytes were examined. Ascytes and receiving the third-party WF kidney transplant
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Fig. 3. Graft survival curves in Lewis rats
pretreated with Brown-Norway (BN) or
Wistar Furth (WF) peripheral blood leuko-
cytes under a short-course of cyclosporine
(CsA) and receiving a BN or WF kidney
transplant. Symbols are: (s) Csa 1 BN leu 1
BN kidney (group 5); (j) CsA 1 BN kid-
ney (group 6); (h) CsA 1 BN leu 1 WF
kidney (group 7); (d) CsA 1 WF leu 1 BN
kidney (group 8); (m) untreated control
(group 9); *P 5 0.0001 vs. groups 6, 7, 9; 8P 5
0.0012 vs. group 8; #P 5 0.014 vs. group 9;
§P 5 0.0084 vs. group 7; ¶P 5 0.0034 vs.
group 6.
Effect of repeated donor leukocyte infusion on kidney
graft survival
Fifty percent of the animals that received the two
infusions of 100 3 106 BN peripheral blood leukocytes
a week apart (group 12) had a prolonged kidney graft
survival (days 27, 28, 32, and 33 post-transplant). The
remaining transplanted rats rejected their graft within 7
to 14 days postsurgery. In this group of animals, graft
survival was lower than that of transplanted Lewis rats
previously receiving a single infusion of the leukocyte
preparation, suggesting that a possible sensitization of
the recipient may have occurred.
Effect of shortening the time interval between donor
cell infusion and kidney transplant
Prolongation of kidney allograft survival was achieved
after reducing the time interval between BN peripheralFig. 4. Stimulation index of mixed lymphocyte reaction (MLR) of re-
blood leukocyte infusion and the transplant from thesponder cells from untreated control Lewis rats (N 5 5), tolerant Lewis
rats (N 5 4), or Lewis rats pretreated with WF leukocytes and rejecting same donor rat strain to 10 days. Rats received a 10 day
a BN graft (N 5 3), to BN stimulator cells. Tolerant responder cells course of CsA starting on the day of cell infusion (groupwere harvested from Lewis hosts with BN kidney allograft surviving
13). In three out of five animals, graft survival was pro-for more than 70 days. Values are mean 6 sd. *P , 0.05 vs. untreated
controls. longed more than 50 days post-transplant, whereas in
the remaining two rats, the kidney allograft failed at 17
and 30 days postsurgery (Table 2). In all Lewis rats given
CsA but not BN leukocyte infusion and transplanted 10shown in Figure 5, in all animals not receiving the con-
days after starting the short-course of the immunosup-comitant immunosuppression with CsA (group 11), BN
pressive agent (group 14), the BN kidney graft failedDNA products in the peripheral blood were demon-
within 10 days postsurgery (P 5 0.004 vs. group 13).strated for up to two days after donor cell infusion. After
the second PCR round, a band was also observed at 10
Effect of donor peripheral blood mononuclear cell orand 20 days, whereas no signal was ever found at 40
polymorphonuclear cell infusion on kidneydays. On the other hand, Lewis rats given BN leukocytes
graft survivaland the short course of CsA (group 10) demonstrated
Table 3 reports BN allograft survival in Lewis ratsthe continuous presence of donor BN DNA until 40 days
recipients of BN PBMC (group 15) or BN PMN (groupafter cell infusion (Fig. 5). Microchimerism persisted in
16) cell infusion under concomitant short-term immuno-four out of six long-term graft recipients 60 to 70 days
post-transplantation. suppression with CsA. Sixty-seven percent of the animals
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Fig. 5. Microchimerism in Lewis rats receiving peripheral leukocytes from BN rats as evaluated by PCR using BN-specific primers. (A) One
round of PCR with primers p1 and p2. (B) Two rounds of PCR, primers p1 and p2, followed by p3 and p2. (Standard) Titration of the specificity
and sensitivity of the PCR for BN rat DNA. DNAs from BN and Lewis blood were mixed at ratios ranging from 1:10 to 1:2500. Lewis DNA was
used as negative control. LW, Lewis. (CsA) Sequential study (1 to 40 days postinfusion) of microchimerism in peripheral blood of Lewis rats
receiving 100 3 106 BN leukocytes intravenously and a concomitant short course CsA treatment (discussed in Experimental design section).
Peripheral blood from BN and Lewis rats was used as positive or negative control, respectively. (No CsA) Sequential study (1 to 40 days postinfusion)
of microchimerism in peripheral blood of Lewis rats receiving 100 3 106 BN leukocytes intravenously but no CsA. Peripheral blood obtained
from BN and Lewis rats was used as positive or negative control, respectively. (Long-term) Detection of microchimerism in peripheral blood from
long-term Lewis recipients of a BN renal graft. Forty days before transplantation, recipient rats received BN leukocytes and a short course of
CsA as described in the Experimental design section. Peripheral blood was obtained 60 to 70 days after transplantation. A specific positive signal
was found in four out of six animals after a two-round PCR. Animals are identified by a number. Results are representative of four independent
experiments.
Table 3. Effect of pretransplant infusion of donor peripheral bloodTable 2. Effect of pretransplant infusion of donor peripheral blood
leukocytes 10 days before transplantation on Brown-Norway mononuclear cells or polymorphonuclear cells on Brown-Norway
kidney allograft survival in Lewis ratskidney allograft survival in Lewis rats
Time of BN leukocyte Time of BN leukocyte
infusion Kidney graft survivalinfusion Kidney graft survival
Groups days pre-transplant days Groups days pre-transplant days
BN-PBMC Day 40 19, 55, .70, .70,CsA alone — 8, 9, 10, 10
BN-Leu 1 CsA Day 10 17, 30, 58, .70, .70a .70, .70a
BN-PMN Day 40 13, 13, 32aAbbreviations are: BN, Brown-Norway rats; Leu, peripheral blood leukocytes;
CsA, cyclosporine (10 mg/kg/day i. m., for 10 days). Abbreviations are: BN, Brown-Norway rats; PBMC, peripheral blood mono-
a P 5 0.004 vs. CsA alone nuclear cells; PMN, polymorphonuclear cells.
a P 5 0.012 vs. BN-PMN group
that received donor PBMC infusion had an indefinite to 1.99 mg/dl). By contrast, Lewis rats given donor PMN
survival of their kidney graft from the same BN donor cell infusion invariably rejected a subsequent BN kid-
strain and had a quite normal renal function after 70 ney allograft, with mild prolongation of graft survival
achieved in only one recipient (P 5 0.012 vs. group 15).days post-transplantation (serum creatinine range, 1.56
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DISCUSSION All together, the above data extend previous observa-
tions that a Lewis donor bone marrow cell suspensionThis study shows that a single intravenous infusion of
under a short course of tacrolimus induced an indefinitedonor peripheral blood leukocytes from BN rats into
survival of Brown Norway liver or heart transplantedMHC-incompatible Lewis recipients largely failed to
100 days after donor cell infusion [18]. Our findings alsoprolong a subsequent kidney allograft from the same
explain why in previous rat studies donor leukocytesdonor transplanted 60, 40, or 30 days after cell infusion.
injected at the time of cardiac transplant with no concom-The failure to observe consistent prolongation of kidney
itant immunosuppression failed to prolong heart survivalgraft survival with the pretransplant donor leukocyte
[17]. Indeed, a short course of immunosuppression, asinfusion alone can be due to an insufficient antigen load
used in this study, seems necessary to allow enough do-provided with 100 3 106 BN cells. However, previous
nor antigen to be presented to host cells to activate thestudies have found that incompatible rats given donor
tolerogenic signals that ultimately lead to the deletionliver or spleen leukocytes at the time of grafting rejected
or functional inactivation of responder T cells [9, 22].the transplanted heart when even greater doses of cells
On this line of investigation, we also found that thewere infused [17]. Alternatively, the lack of donor leuko-
short course of CsA treatment is mandatory to allowcyte engraftment may explain the failure to prolong kid-
engraftment of donor BN leukocytes, as documented byney allograft survival. Starzl et al have indicated that
the persistent microchimerism by PCR up to 40 daysengraftment of donor bone marrow cells depends on the
after cell infusion in animals given a concomitant immu-adequacy of concomitant immunosuppression given to
nosuppression with CsA, but not in those that did notprotect donor leukocytes from host-reactive T cells [21].
receive the drug.According to Starzl et al, an ideal interaction of donor
It has been suggested that actively acquired toleranceand recipient leukocytes is required to establish a very
is concordant with donor lymphomyeloid cell chimerism,low-grade stimulatory state, which is necessary for recip-
since the early discovery of a classic neonatal tolerancerocal nonreactivity among the two cell populations [6,
[9, 23]. In most long-term graft recipients, we demon-
7, 9, 21]. Taking advantage of this experience, we studied
strated peripheral blood microchimerism up to 60 to 70
the effect of donor leukocyte infusion on subsequent days post-transplantation. This suggests that the persis-
kidney allograft survival in rats given some immunosup- tence of donor cells in the host may be important to
pressants at the time of cell infusion. Thus, in these drive the sequence of events that ultimately maintains
experiments, a short course of CsA was started on the donor-specific graft unresponsiveness [24, 25]. However,
same day of infusion of the donor leukocyte preparation. controversies remain as to whether the cellular microchi-
Under this treatment condition, prolongation of graft merism is the cause or rather the result of graft accep-
survival was achieved when the kidney transplant was tance in long-term recipients [26–28].
performed 40 days later, with some animals even devel- Failure to induce permanent tolerance in 100% of
oping tolerance to the allograft. By contrast, CsA pre- animals could possibly depend on the initial donor leuko-
treatment alone did not affect graft survival. Our findings cyte load, which might not have been enough to reach
suggest that the short course of CsA treatment allowed the threshold to fully drive a tolerogenic signal. Recent
an engraftment of donor leukocytes. They also indicate findings in rodents and humans found that the success
that these cells possess more potential for enhancing the of donor bone marrow infusion could only be achieved
inherent, but low tolerogenic potential of donor kidney when a high enough dose of donor marrow-derived stem
related to its smaller “passenger leukocyte” components cells was used [17, 29].
than other whole organs such as liver [21]. This effect We also found that repeated-donor leukocyte infu-
was donor specific because a third-party kidney allograft sions under concomitant immunosuppression with CsA
was invariably rejected. However, when third-party pe- not only failed to achieve tolerance, but even sensitized
ripheral blood leukocytes were infused, some prolonga- the graft recipients to the extent that kidney graft sur-
tion of BN kidney allograft survival was also observed. vival was actually shorter than what we obtained with the
This unexpected finding is difficult to interpret. One pos- pretransplant infusion of a single leukocyte preparation.
sibility is that WF leukocytes may share minor histo- This is in line with an earlier clinical observation that a
compatibility antigens with BN kidneys or leukocytes, protocol of repeated pretransplant donor-specific blood
whereas this is not the case for BN leukocytes and WF transfusion is associated with sensitization of the recipi-
kidney. This is in line with the in vitro observation that ent and may preclude transplantation in near 14 to 30%
the MLR response of Lewis cells from animals pre- of the donor-recipient pairs [30–32].
treated with WF leukocytes and receiving BN kidney In this study, kidney grafts were first performed on
was not as high as that of lymphocytes from untreated day 40 after the infusion of donor leukocytes in the Lewis
Lewis rats, but was still higher than that of responder recipient. However, similar results have been achieved
by transplanting kidneys 10 days after donor leukocytecells from tolerant rats.
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infusion, always depending on short-term CsA. This mocytes bearing the specific donor T-cell receptor. These
results are consistent with the interpretation that intra-would open interesting perspectives of shortening the
interval between donor cell infusion and the subsequent thymic clonal deletion is the only significant mechanism
by which tolerance is maintained in these mixed chimerastransplant, keeping in mind future clinical developments.
The heterogeneity of the leukocyte population infused [42]. In line with these findings are also previous observa-
tions by our group and other investigators that directin the host before kidney transplantation precludes
definite conclusions on the properties of prolonging graft injection of donor cells/antigens into the thymus is capa-
ble of inducing donor-specific tolerance to a subsequentsurvival afforded per se by any specific cell lineages in
the preparation. In additional experiments, however, we tissue or vascularized organ allograft through activation
of a process of programmed cell death/apoptosis of ma-documented that donor PBMCs but not PMNs in the
preparation contributed to prolong kidney allograft sur- turing host thymocytes [44–46].
All together, these results are consistent with the possi-vival, with tolerance achieved in most animals. This is
in line with previous findings in a model of rat small bility that after systemic infusion, donor mononuclear
cells and few hematopoietic precursor cells migrate tobowel transplantation in which prolongation of graft sur-
vival was achieved by donor splenocyte infusion via the the thymus shortly thereafter and become capable of
negatively selecting newly developing T cells. Eventu-portal vein under a short course of the immunosuppres-
sive agent FK506 [33]. Which one is the specific donor ally, the peripheral T-cell components would be devoid
of alloreactive cell populations. This mechanism maycell lineage that is actively involved remains ill defined.
Very recently, it has been shown in mice that T cells operate in concert with veto cells present in the donor
peripheral blood leukocytes providing a reliable meanfrom the spleen of the donor facilitate the acceptance
of the allogeneic skin engraftment when injected into of ensuing donor- and host-specific unresponsiveness.
Thus, pretransplant donor leukocyte infusion underthe portal vein of the recipients, an effect that was po-
tentiated when donor bone marrow cells were also given the appropriate conditions tips the immune balance to-
ward improved graft acceptance. The tolerance potentialintravenously [34]. Thus, the possibility exists that in our
experimental conditions, the donor T-cell component of of such treatment is a further step toward the ultimate
goal of inducing donor-specific tolerance to allografts,the mononuclear cell population we infused into the
recipient may have played an important role in pro- leaving intact the response to third-party antigens.
This approach has obvious implications for clinicallonging the survival of the subsequent kidney allograft.
Calne and Davies have suggested a critical role of class transplantation.
I antigens released by donor cells in the circulation for
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